Modulating TNFα activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia
Background C-type lectin-like molecule 1 (CLL-1) is highly expressed in acute myeloid leukemia (AML) but is absent in primitive hematopoietic progenitors, making it an attractive target for a chimeric antigen receptor (CAR) T-cell therapy. Here, we optimized our CLL-1 CAR for anti-leukemic activity...
Saved in:
| Main Authors: | Maksim Mamonkin, Malcolm K Brenner, Norihiro Watanabe, Pinar Ataca Atilla, Mary K McKenna, Haruko Tashiro, Madhuwanti Srinivasan, Feiyan Mo, Brian Wesley Simons, Alexandra McLean Stevens, Michele S Redell, Helen E Heslop, Erden Atilla |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e001229.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Modulating TNFα Activity to Address Cytokine Related Toxicity
by: Pinar Ataca Atilla, et al.
Published: (2025-02-01) -
Successful Bosutinib Experience in an Elderly Acute Lymphoblastic Leukemia Patient with Suspected Central Nervous System Involvement Transformed from Chronic Myeloid Leukemia
by: Erden Atilla, et al.
Published: (2015-01-01) -
CAR-T CELL THERAPY IN CLL
by: Selver Kurt
Published: (2024-12-01) -
REAL-WORLD ANALYSIS OF PATIENTS WITH CLL TREATED WITH IBRUTINIB: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN REGISTRY OF CLL
by: V Pfister, et al.
Published: (2024-10-01) -
Development of a modular patient-reported outcome and experience measure on patient needs and benefits in CLL (PBI-CLL)
by: Beke Hester, et al.
Published: (2025-04-01)